106 results on '"Wojdyla, Daniel"'
Search Results
2. Trans-Balance: Reducing demographic disparity for prediction models in the presence of class imbalance
3. Temporal Trends in Risk Factors of Periprocedural Stroke in Patients Undergoing Percutaneous Coronary Intervention: Insights from the ACC NCDR CathPCI Registry
4. TCT-406 Effect of Antithrombotic Strategies on Total Outcome Events in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS
5. ASSOCIATION OF HRCT PATTERNS AND TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS) IN THE ILD-PRO REGISTRY
6. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension
7. Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials
8. Long Term Health-Related Quality of Life and Symptom Severity Following Hysterectomy, Myomectomy, or Uterine Artery Embolization for the Treatment of Symptomatic Uterine Fibroids
9. WOMEN IN EXPLORER-HCM HAD MORE SEVERE HEART FAILURE AT BASELINE BUT SIMILAR, OR GREATER, RESPONSE TO MAVACAMTEN
10. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS OF OLDER AGE AND LONGER DURATION OF DIAGNOSIS: ANALYSIS OF THE EXPLORER-HCM TRIAL
11. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS WITH OR WITHOUT HYPERTENSION: ANALYSIS OF THE EXPLORER-HCM TRIAL
12. OBSTRUCTIVE HCM PATIENTS IN EXPLORER-HCM WITH HIGH LEFT VENTRICULAR FILLING PRESSURES HAD MORE SEVERE HEART FAILURE BUT SIMILAR OR GREATER RESPONSE TO MAVACAMTEN
13. Comparing the Classification of Percutaneous Coronary Interventions Using the 2012 and 2017 Appropriate Use Criteria: Insights From 245,196 Patients in the NCDR CathPCI Registry
14. TCT-20 Relative Benefit of Double Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Randomized Earlier Versus Later After Index Coronary Event: Insights From the AUGUSTUS Trial
15. TCT-586 Outcomes and Institutional Variation in Arterial Access Choice Among Patients With Acute Myocardial Infarction and Cardiogenic Shock Undergoing PCI: An Analysis From the CathPCI Registry
16. TCT-1 Bleeding in Patients With Atrial Fibrillation and Acute Coronary Syndrome or PCI Treated With Antithrombotic Therapy: Insights From the AUGUSTUS Trial
17. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
18. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).
19. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention
20. TCT-167 Utilization Rates and In-Hospital Outcomes Associated With Intravascular Imaging–Guided PCI in the USA: An Analysis of the NCDR CathPCI Registry
21. Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance
22. EFFECT OF APIXABAN VERSUS VITAMIN K ANTAGONIST AND ASPIRIN VERSUS PLACEBO ON DAYS ALIVE AND OUT OF HOSPITAL IN THE AUGUSTUS RANDOMIZED CONTROLLED TRIAL
23. NATIONWIDE TRENDS AND OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTIONS FOLLOWING DIAGNOSTIC ANGIOGRAPHY PERFORMED BY NON-INTERVENTIONAL CARDIOLOGIST VERSUS INTERVENTIONALISTS: INSIGHTS FROM THE CATHPCI REGISTRY
24. Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?
25. Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry
26. Contemporary Use of Veno-arterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter Rescue Registry
27. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial)
28. Prevalence, treatment, and control of severe hyperlipidemia
29. The association between triglycerides and incident cardiovascular disease: What is “optimal”?
30. Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial
31. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
32. APIXABAN VERSUS WARFARIN AND ASPIRIN VERSUS PLACEBO ACCORDING TO RENAL FUNCTION AFTER ACUTE CORONARY SYNDROME OR PCI IN ATRIAL FIBRILLATION: INSIGHTS FROM THE AUGUSTUS TRIAL
33. Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction
34. Natural History and Outcomes of Patients with Critical Limb Ischemia in the Euclid Trial
35. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD
36. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)
37. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry
38. Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial
39. Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
40. Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris
41. THE IMPACT OF HYPERLIPIDEMIA ON CARDIOVASCULAR RISK IN OLDER ADULTS AGE ≥ 75: RESULTS FROM THE NHLBI POOLED COHORTS
42. PREVALENCE & CONTROL OF EXTREMELY HIGH LDL CHOLESTEROL: AN ANALYSIS IN >10,000,000 INDIVIDUALS ACROSS 429 HEALTH SYSTEMS
43. RECALLED ICD GENERATORS IN THE NCDR-ICD REGISTRY: OUTCOMES AND SURVEILLANCE IMPLICATIONS
44. TRANSFUSIONS, WITH OR WITHOUT CONCOMITANT BLEEDING, ARE ASSOCIATED WITH HIGH SHORT-TERM MORTALITY IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULATION
45. Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial)
46. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome
47. Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery
48. COMPARISON OF RATES OF BLEEDING AND VASCULAR COMPLICATIONS BEFORE, DURING, AND AFTER TRIAL ENROLLMENT IN THE SAFE-PCI TRIAL FOR WOMEN
49. AD HOC PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY
50. THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.